TROP-2–Targeted ADCs for NSCLC: Integrating a New Therapeutic Option

Get up to date on the latest clinical evidence and benefits and nuances of incorporating TROP-2–targeted antibody–drug conjugates into the care of patients with advanced NSCLC by reviewing a CME-certified on-demand webcast and downloadable slides derived from a live symposium, along with a commentary where experts answer frequently asked questions. 

Share

Program Content

Activities

ADCs and TROP-2 in NSCLC
Antibody–Drug Conjugates and the Role of TROP-2 in NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 19, 2024

TROP-2 ADCs in NSCLC: Clinical Data
Latest Therapeutic Advancements in Targeting TROP-2 in NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 19, 2024

Expires: March 18, 2025

TROP-2 ADCs in NSCLC: Safety
AE Management With TROP-2 ADCs in NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 19, 2024

Activities

TROP2 ADCs for NSCLC
TROP-2–Targeted ADCs for NSCLC: ​Integrating a New Therapeutic Option
Video
Congratulations: You achieved a completion on 04/09/2022

Released: April 10, 2024

Expires: April 09, 2025

Activities

TROP 2 Targeted ADCs in NSCLC
Mapping TROP-2–Targeted ADCs Into the NSCLC Treatment Landscape
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 02, 2024

Expires: May 01, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.